Patent intelligence · US
US 10450340
3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
Patent details — US 10450340
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 22, 2019
- Expiration
- Oct 17, 2039
- Applicant
- Monopar Therapeutics Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/704, A61P, A61P35/00
Quick answer
US 10450340 (3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation) is held by Monopar Therapeutics Inc.. Status: granted. Granted Oct 22, 2019. Expires Oct 17, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Monopar Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/704, A61P, A61P35/00
More from Monopar Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10450340?
US 10450340 (3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation) is held by Monopar Therapeutics Inc.. Status: granted. Granted Oct 22, 2019. Expires Oct 17, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10450340?
Monopar Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 10450340 expire?
Our index shows an expiration date of Oct 17, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.